Moderna said higher costs and a decline in demand for its Omicron-targeting Covid-19 doses also hit its performance.Photo: Simon Simard for The Wall Street Journal
Moderna Inc. said third-quarter revenue fell by nearly a third and cut its outlook as supply constraints sap up to $3 billion in sales this year.
The Cambridge, Mass.-based pharmaceutical company on Thursday said higher costs and a decline in demand for its Omicron-targeting Covid-19 doses also hit its performance.
Already a member? Sign In
